Gainplan’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Gainplan’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,000	Closed	-$246K	–	73
2021 Q3	$246K	Sell	6,000 -17,353	-74%	-$732K	0.11%	48
2021 Q2	$928K	Buy	23,353 +11,467	+96%	+$428K	0.37%	27
2021 Q1	$415K	Buy	11,886 +2,313	+24%	+$86.7K	0.18%	39
2020 Q4	$298K	Buy	+9,573	New	+$291K	0.16%	39

Other funds holding GERM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Gainplan's GERM Position: Q4 2021 in Review

Gainplan sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q4 2021, closing a stake of 6,000 shares — an estimated $246K sold.

Gainplan first reported a position in GERM in Q4 2020 and held it in 4 quarters. The position peaked at $928K in Q2 2021. 30 funds tracked by Wall St. Rank hold GERM as of Q4 2021.

Gainplan reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q4 2021 after selling out during the quarter.
Gainplan sold 6,000 Amplify Treatments, Testing and Advancements ETF shares in Q4 2021, an estimated $246K.
Gainplan first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 4 quarters.
Gainplan's Amplify Treatments, Testing and Advancements ETF position peaked at $928K in Q2 2021.
30 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q4 2021.

Based on Gainplan's 13F filing for Q4 2021, filed 4 Feb 2022.